XML 45 R53.htm IDEA: XBRL DOCUMENT
v2.4.1.9

License and Collaboration Agreements - Additional Information (Detail) (USD $) | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 0 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2014 | Dec. 31, 2009 | Feb. 29, 2012 | Jun. 30, 2013 | Dec. 31, 2007 | Jun. 30, 2014 | Dec. 31, 2009 | Sep. 16, 2014 | Dec. 31, 2010 | Dec. 31, 2013
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones | $ 130,300,000 nktr_PotentialDevelopmentMilestones |  |  |  |  |  |  |  |  |
MOVANTIK [Member] | US and EU Commercial Launch [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent payments receivable based on development events regulatory to be pursued and completed solely by others | 140,000,000 nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents / us-gaap_ProductOrServiceAxis = nktr_FoodAndDrugAdministrationAndEuropeanMedicinesAgencyApprovalMember / us-gaap_TypeOfArrangementAxis = nktr_MovantikMember |  |  |  |  |  |  |  |  |
MOVANTIK [Member] | United States [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent payments receivable based on development events regulatory to be pursued and completed solely by others | 100,000,000 nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents / us-gaap_StatementGeographicalAxis = country_US / us-gaap_TypeOfArrangementAxis = nktr_MovantikMember |  |  |  |  |  |  |  |  |
MOVANTIK [Member] | European Union [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent payments receivable based on development events regulatory to be pursued and completed solely by others | 40,000,000 nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents / us-gaap_StatementGeographicalAxis = us-gaap_EuropeanUnionMember / us-gaap_TypeOfArrangementAxis = nktr_MovantikMember |  |  |  |  |  |  |  |  |
Roche [Member] | License Extension Option [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  | 31,000,000 nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement / us-gaap_DeferredRevenueArrangementTypeAxis = nktr_LicenseOptionMember / dei_LegalEntityAxis = nktr_RocheMember |  |  |  |  |  |  |  |
Roche [Member] | MIRCERA [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred revenue | 10,700,000 us-gaap_DeferredRevenue / dei_LegalEntityAxis = nktr_RocheMember / us-gaap_TypeOfArrangementAxis = nktr_MirceraMember |  |  |  |  |  |  |  |  |
Allocated consideration |  |  | 27,000,000 nktr_AllocatedConsideration / dei_LegalEntityAxis = nktr_RocheMember / us-gaap_TypeOfArrangementAxis = nktr_MirceraMember |  |  |  |  |  |  |
Consideration received for product delivered in 2013 | 18,600,000 nktr_ConsiderationReceivedForProductDelivered / dei_LegalEntityAxis = nktr_RocheMember / us-gaap_TypeOfArrangementAxis = nktr_MirceraMember |  |  |  |  |  |  |  |  |
Roche [Member] | MIRCERA [Member] | Performance-based Milestone Payments [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  | 22,000,000 nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement / dei_LegalEntityAxis = nktr_RocheMember / us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis = nktr_PerformanceMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = nktr_MirceraMember |  |  |  |  |  |  |
Roche [Member] | MIRCERA [Member] | Upfront Payment Arrangement in 2007 [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  | 5,000,000 nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement / us-gaap_DeferredRevenueArrangementTypeAxis = us-gaap_UpFrontPaymentArrangementMember / dei_LegalEntityAxis = nktr_RocheMember / us-gaap_TypeOfArrangementAxis = nktr_MirceraMember |  |  |  |  |  |  |
Roche [Member] | PEGASYS [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred revenue | 5,100,000 us-gaap_DeferredRevenue / dei_LegalEntityAxis = nktr_RocheMember / us-gaap_TypeOfArrangementAxis = nktr_PegasysMember |  |  |  |  |  |  |  |  |
Roche [Member] | PEGASYS and MIRCERA [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred revenue | 4,600,000 us-gaap_DeferredRevenue / dei_LegalEntityAxis = nktr_RocheMember / us-gaap_TypeOfArrangementAxis = nktr_PegasysAndMirceraMember |  |  |  |  |  |  |  |  |
Bayer Healthcare LLC [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones | 50,000,000 nktr_PotentialDevelopmentMilestones / dei_LegalEntityAxis = nktr_BayerHealthcareLlcMember |  |  |  |  |  |  |  |  |
Deferred revenue | 20,800,000 us-gaap_DeferredRevenue / dei_LegalEntityAxis = nktr_BayerHealthcareLlcMember |  |  |  |  |  |  |  |  |
Payment made to Bayer for cost of Phase 3 clinical trial |  |  |  | 10,000,000 nktr_PaymentForReimbursementOfCosts / dei_LegalEntityAxis = nktr_BayerHealthcareLlcMember |  |  |  |  |  |
Bayer Healthcare LLC [Member] | Performance-based Milestone Payments [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments | 30,000,000 nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement / dei_LegalEntityAxis = nktr_BayerHealthcareLlcMember / us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis = nktr_PerformanceMilestonePaymentsMember |  |  |  |  |  |  |  |  |
Development milestone achieved in 2013 | 10,000,000 nktr_DevelopmentMilestonePaymentReceived / dei_LegalEntityAxis = nktr_BayerHealthcareLlcMember / us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis = nktr_PerformanceMilestonePaymentsMember |  |  |  |  |  |  |  |  |
Bayer Healthcare LLC [Member] | Upfront Payment Arrangement in 2007 [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  | 40,000,000 nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement / us-gaap_DeferredRevenueArrangementTypeAxis = us-gaap_UpFrontPaymentArrangementMember / dei_LegalEntityAxis = nktr_BayerHealthcareLlcMember |  |  |  |  |
Ophthotech Corporation [Member] | Fovista [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones | 9,500,000 nktr_PotentialDevelopmentMilestones / dei_LegalEntityAxis = nktr_OphthotechCorporationMember / us-gaap_TypeOfArrangementAxis = nktr_FovistaMember |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  | 19,750,000 nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement / dei_LegalEntityAxis = nktr_OphthotechCorporationMember / us-gaap_TypeOfArrangementAxis = nktr_FovistaMember |  |  |  |
Deferred revenue | 18,900,000 us-gaap_DeferredRevenue / dei_LegalEntityAxis = nktr_OphthotechCorporationMember / us-gaap_TypeOfArrangementAxis = nktr_FovistaMember |  |  |  |  |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIKTM (NKTR-118) and MOVANTIKTM fixed-dose combination program (NKTR-119) [Member] | Upfront Payment Arrangement in 2007 [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  | 125,000,000 nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement / us-gaap_DeferredRevenueArrangementTypeAxis = us-gaap_UpFrontPaymentArrangementMember / dei_LegalEntityAxis = nktr_AstraZenecaAbMember / us-gaap_TypeOfArrangementAxis = nktr_MovantikAndMovantikFixedDoseCombinationProgramMember |  |  |
AstraZeneca AB [Member] | MOVANTIK [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  | 70,000,000 nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement / dei_LegalEntityAxis = nktr_AstraZenecaAbMember / us-gaap_TypeOfArrangementAxis = nktr_MovantikMember |  |
Contingent payments receivable based on development events regulatory to be pursued and completed solely by others | 140,000,000 nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents / dei_LegalEntityAxis = nktr_AstraZenecaAbMember / us-gaap_TypeOfArrangementAxis = nktr_MovantikMember |  |  |  |  |  |  |  |  |
Potential reduction in U.S. royalty rate for repayment |  |  |  |  |  |  |  | 2.00%nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired / dei_LegalEntityAxis = nktr_AstraZenecaAbMember / us-gaap_TypeOfArrangementAxis = nktr_MovantikMember |  |
Percentage of post approval study costs to repay |  |  |  |  |  |  |  | 33.00%nktr_PercentageOfPostApprovalStudyCostsToRepay / dei_LegalEntityAxis = nktr_AstraZenecaAbMember / us-gaap_TypeOfArrangementAxis = nktr_MovantikMember |  |
Maximum potential reduction in royalties |  |  |  |  |  |  |  | 35,000,000 nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies / dei_LegalEntityAxis = nktr_AstraZenecaAbMember / us-gaap_TypeOfArrangementAxis = nktr_MovantikMember |  |
AstraZeneca AB [Member] | MOVANTIK [Member] | Pre-approval Cardiovascular Safety Study Not Required [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent payments received based on development events |  |  |  |  |  |  |  | 35,000,000 nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents / dei_LegalEntityAxis = nktr_AstraZenecaAbMember / us-gaap_ProductOrServiceAxis = nktr_CardiovascularSafetyStudyNotRequiredMember / us-gaap_TypeOfArrangementAxis = nktr_MovantikMember |  |
AstraZeneca AB [Member] | Movantik Fixed-dose Combination Program [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent payments receivable based on development events regulatory to be pursued and completed solely by others | 75,000,000 nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents / dei_LegalEntityAxis = nktr_AstraZenecaAbMember / us-gaap_TypeOfArrangementAxis = nktr_MovantikFixedDoseCombinationProgramMember |  |  |  |  |  |  |  |  |
Baxter Healthcare [Member] | BAX 855 (Hemophilia) [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones | 20,000,000 nktr_PotentialDevelopmentMilestones / dei_LegalEntityAxis = nktr_BaxterHealthcareMember / us-gaap_TypeOfArrangementAxis = nktr_HemophiliaMember |  |  |  |  |  |  |  |  |
Deferred revenue | 0 us-gaap_DeferredRevenue / dei_LegalEntityAxis = nktr_BaxterHealthcareMember / us-gaap_TypeOfArrangementAxis = nktr_HemophiliaMember |  |  |  |  |  |  |  |  |
Development milestones achieved | 8,000,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / dei_LegalEntityAxis = nktr_BaxterHealthcareMember / us-gaap_TypeOfArrangementAxis = nktr_HemophiliaMember |  |  |  |  |  |  |  |  |
Amgen, Inc. [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  | 50,000,000 nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement / dei_LegalEntityAxis = nktr_AmgenIncMember |
Deferred revenue | 29,200,000 us-gaap_DeferredRevenue / dei_LegalEntityAxis = nktr_AmgenIncMember |  |  |  |  |  |  |  |  |
Affymax, Inc. [Member] | OMONTYS [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred revenue recognized |  |  |  |  |  |  |  |  |  | 6,700,000 us-gaap_DeferredRevenueRevenueRecognized / dei_LegalEntityAxis = nktr_AffymaxIncMember / us-gaap_TypeOfArrangementAxis = nktr_OmontysMember
Other [Member] |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones | 53,800,000 nktr_PotentialDevelopmentMilestones / dei_LegalEntityAxis = nktr_OtherPartnerMember |  |  |  |  |  |  |  |  |
Development milestones achieved | $ 9,000,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / dei_LegalEntityAxis = nktr_OtherPartnerMember |  |  |  |  |  |  |  |  |

X
- Definition Allocated Consideration + References No definition available. + Details
Name: | nktr_AllocatedConsideration
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Consideration received for product delivered. + References No definition available. + Details
Name: | nktr_ConsiderationReceivedForProductDelivered
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent payments receivable based on development events. + References No definition available. + Details
Name: | nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contingent payments received based on development events. + References No definition available. + Details
Name: | nktr_ContingentPaymentsReceivedBasedOnDevelopmentEvents
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development milestone payment received. + References No definition available. + Details
Name: | nktr_DevelopmentMilestonePaymentReceived
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment made to Bayer for cost of Phase 3 clinical trial. + References No definition available. + Details
Name: | nktr_PaymentForReimbursementOfCosts
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of post approval study costs to repay. + References No definition available. + Details
Name: | nktr_PercentageOfPostApprovalStudyCostsToRepay
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential development milestones. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential Reduction In Future Royalty Payments To Repay Post Approval Studies + References No definition available. + Details
Name: | nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potential royalty reduction on US sales to repay post-approval study if required + References No definition available. + Details
Name: | nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront and Milestone Payments Received Under License Agreement + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=nktr_AffymaxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AstraZenecaAbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BaxterHealthcareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_OphthotechCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_OtherPartnerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_RocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MovantikMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |